Antara News·Indonesia·Wednesday, October 7, 2026 at 12:11 PM UTC

Indonesia pushes national plasma ecosystem to boost health resilience

Translate

Mecca Yumna Ning Prisie, Yashinta Difa

Jakarta (ANTARA) - The Health Ministry is drafting regulations to establish an independent national plasma ecosystem to strengthen health resilience, though officials noted three key challenges must be addressed.

Aswardi, Head of the Ministry's Working Group on Blood and Immunological Disorders, stated in Jakarta on Wednesday that limited resources, public donor readiness, and cross-sector coordination remain the main hurdles to securing plasma-derived medicinal products (PDMPs).

"The implementation of PDMPs depends on the public being ready and willing to play an active role in donation," Aswardi said.

PDMPs are essential therapies used to treat a wide array of life-threatening conditions, including primary immunodeficiency, hemophilia, and various rare, chronic diseases.

Dita Novianti Sugandi Argadireja, the ministry's Director of Pharmaceutical Production and Distribution, highlighted that securing an affordable, high-quality supply of these therapies is a cornerstone of national health resilience.

"When we speak of plasma, we are not merely discussing a blood component; we are talking about hope and the survival of patients who require plasma-based therapies," Argadireja stated, stressing the need for integrated collaboration among government agencies, health institutions, blood management units, industry, and donor communities.

The regulatory drive coincides with International Plasma Awareness Week 2026, where the Health Ministry partnered with biopharmaceutical company Takeda Life Sciences to build the country's first PDMP ecosystem, supported by an initial $30 million investment.

Health Minister Budi Gunadi Sadikin noted that the partnership reflects the government's commitment to localizing advanced healthcare manufacturing and mitigating global supply chain risks.

Under the agreement, Takeda has been designated as an authorized pharmaceutical firm to carry out plasma fractionation, laying the groundwork for domestic plasma processing.

The initial capital injection marks the start of a two-year plan to build a national plasma bank network, with the first facility scheduled to operate by 2027.

View the original on Antara News →

KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.